Results 121 to 130 of about 20,731 (163)
Some of the next articles are maybe not open access.
Infection Control & Hospital Epidemiology, 1990
Aztreonam, the first licensed monobactam in the United States, is a β-lactam antimicrobial agent with a unique structure and in vitro spectrum of activity. The drug is active only against gram-negative aerobic bacteria in vitro, thus resembling the spectrum of aminoglycosides, but displays the safety profile typical of β-lactam agents.
A R, Tunkel, W M, Scheld
+8 more sources
Aztreonam, the first licensed monobactam in the United States, is a β-lactam antimicrobial agent with a unique structure and in vitro spectrum of activity. The drug is active only against gram-negative aerobic bacteria in vitro, thus resembling the spectrum of aminoglycosides, but displays the safety profile typical of β-lactam agents.
A R, Tunkel, W M, Scheld
+8 more sources
Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 1986
Aztreonam is a new, totally synthetic beta‐lactamase agent — the first monobactam. It is highly resistant to hydrolytic inactivation caused by plasmid‐mediated (except PSE‐2 enzyme found in some Pseudomonas species) or chromosomally mediated beta‐lactamases (except for K1 produced by rare strains of Klebsiella oxytoca).
S J, Childs, G P, Bodey
openaire +3 more sources
Aztreonam is a new, totally synthetic beta‐lactamase agent — the first monobactam. It is highly resistant to hydrolytic inactivation caused by plasmid‐mediated (except PSE‐2 enzyme found in some Pseudomonas species) or chromosomally mediated beta‐lactamases (except for K1 produced by rare strains of Klebsiella oxytoca).
S J, Childs, G P, Bodey
openaire +3 more sources
Nature Reviews Drug Discovery, 2010
In February 2010, aztreonam for inhalation solution (Cayston; Gilead) - an inhalable formulation of the monobactam antibiotic aztreonam and lysine - was approved by the US FDA to improve respiratory symptoms in patients with cystic fibrosis infected with Pseudomonas aeruginosa.
O'Sullivan, Brian P. +2 more
openaire +3 more sources
In February 2010, aztreonam for inhalation solution (Cayston; Gilead) - an inhalable formulation of the monobactam antibiotic aztreonam and lysine - was approved by the US FDA to improve respiratory symptoms in patients with cystic fibrosis infected with Pseudomonas aeruginosa.
O'Sullivan, Brian P. +2 more
openaire +3 more sources
Obstetrics and Gynecology Clinics of North America, 1992
Aztreonam is a synthetic monobactam antibiotic that has excellent activity against aerobic gram-negative bacilli. It can be used as a single agent for the treatment of upper urinary tract infections caused by organisms resistant to the cephalosporins and ampicillin.
openaire +3 more sources
Aztreonam is a synthetic monobactam antibiotic that has excellent activity against aerobic gram-negative bacilli. It can be used as a single agent for the treatment of upper urinary tract infections caused by organisms resistant to the cephalosporins and ampicillin.
openaire +3 more sources
The Pediatric Infectious Disease Journal, 1989
Monocyclic beta-lactam antibiotics (monobactams) are structurally unique from the traditional bicyclic beta-lactams because of their single ring configuration. Aztreonam, the first of these monobactams, has been studied extensively in order to determine its pharmacologic and pharmacokinetic profile in adults and children with bacterial infections.
openaire +2 more sources
Monocyclic beta-lactam antibiotics (monobactams) are structurally unique from the traditional bicyclic beta-lactams because of their single ring configuration. Aztreonam, the first of these monobactams, has been studied extensively in order to determine its pharmacologic and pharmacokinetic profile in adults and children with bacterial infections.
openaire +2 more sources
Drug Intelligence & Clinical Pharmacy, 1985
Aztreonam is the first synthetic monobactam to undergo clinical studies in the U.S. Aztreonam has excellent activity against P. aeruginosa and Enterobacteriaceae, but poor activity against anaerobic and gram-positive organisms. Aztreonam has poor oral bioavailability, but can be given intramuscularly or intravenously in doses of 1–2 g q6–12h.
openaire +2 more sources
Aztreonam is the first synthetic monobactam to undergo clinical studies in the U.S. Aztreonam has excellent activity against P. aeruginosa and Enterobacteriaceae, but poor activity against anaerobic and gram-positive organisms. Aztreonam has poor oral bioavailability, but can be given intramuscularly or intravenously in doses of 1–2 g q6–12h.
openaire +2 more sources
Infectious Disease Clinics of North America, 1989
To date, clinical use of aztreonam has been remarkably restrained and widespread enthusiasm for addition to hospital formularies similarly moderate. Its most accepted indication appears to be in gram-negative bacillary infections in the penicillin-allergic individual where one might ordinarily use an extended spectrum penicillin or a third generation ...
openaire +2 more sources
To date, clinical use of aztreonam has been remarkably restrained and widespread enthusiasm for addition to hospital formularies similarly moderate. Its most accepted indication appears to be in gram-negative bacillary infections in the penicillin-allergic individual where one might ordinarily use an extended spectrum penicillin or a third generation ...
openaire +2 more sources